Evidence map›Paper›PMID 37483698›Full record

ArticleHeliyon2023

Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients.

Amr Elkholy, Nagavardhini Avuthu, Mohammed Abdalla, Michael Behring, Prachi Bajpai, Hyung-Gyoon Kim, Doaa Header, Reham Ah Abo Elwafa, Hesham Saed, Amira Embaby and 17 more

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. The Phylum Fusobacteriota Is Associated with Colorectal Cancer-Specific Mortality: Results from the Translational Research Program in Cancer Differences across Populations.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Characteristics of gut microbiota in high-methylated colorectal cancer.International journal of clinical oncology · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Opportunistic pathogeniScience · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 6 institutions in 3 countries.

Amr ElkholyDepartment of Pathology, University of Alabama at Birmingham, AL, USA.
Nagavardhini AvuthuDepartment of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE, USA.
Mohammed AbdallaDepartment of Biotechnology, Institute of Graduate Studies and Research, Alexandria University, Alexandria, Egypt.
Michael BehringDepartment of Pathology, University of Alabama at Birmingham, AL, USA.
Prachi BajpaiDepartment of Pathology, University of Alabama at Birmingham, AL, USA.
Hyung-Gyoon KimDepartment of Pathology, University of Alabama at Birmingham, AL, USA.
Doaa HeaderDepartment of Gastroenterology, Faculty of Medicine, University of Alexandria, Egypt.
Reham Ah Abo ElwafaDepartment of Clinical Pathology, Faculty of Medicine, University of Alexandria, Egypt.
Hesham SaedDepartment of Biotechnology, Institute of Graduate Studies and Research, Alexandria University, Alexandria, Egypt.
Amira EmbabyDepartment of Biotechnology, Institute of Graduate Studies and Research, Alexandria University, Alexandria, Egypt.
Nefertiti El-NikhelyDepartment of Biotechnology, Institute of Graduate Studies and Research, Alexandria University, Alexandria, Egypt.
Sarah ObuyaMoi Teaching and Referral Hospital, Moi University, Kesses, Kenya.
Mostafa MohamedDepartment of Pathology, University of Alabama at Birmingham, AL, USA.
Ahmed Ashour BadawyDepartment of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, University of Alexandria, Egypt.
Ahmed NawarDepartment of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, University of Alexandria, Egypt.
Farrukh AfaqDepartment of Pathology, University of Alabama at Birmingham, AL, USA.
Laura Q RogersDivision of Preventive Medicine, University of Alabama at Birmingham, AL, USA.
Sejong BaeDivision of Preventive Medicine, University of Alabama at Birmingham, AL, USA.
James M ShikanyDivision of Preventive Medicine, University of Alabama at Birmingham, AL, USA.
Lori Brand BatemanDivision of Preventive Medicine, University of Alabama at Birmingham, AL, USA.
Mona FouadDivision of Preventive Medicine, University of Alabama at Birmingham, AL, USA.
Mansoor SalehDepartment of Hematology-Oncology, Aga Khan University, Nairobi, Kenya.
Temesgen SamuelTuskegee University College of Veterinary Medicine Tuskegee, AL, USA.
Sooryanarayana VaramballyDepartment of Pathology, University of Alabama at Birmingham, AL, USA.
Chittibabu GudaDepartment of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE, USA.
Waleed ArafatDepartment of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, University of Alexandria, Egypt.
Upender ManneDepartment of Pathology, University of Alabama at Birmingham, AL, USA.
University of Alabama at Birmingham · USAlexandria University · EGUniversity of Nebraska Medical Center · USAga Khan University Nairobi · KEMoi University · KETuskegee University · US

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Omer Jamy · 1985 to 2026
$165.9M
UNMC Structural Biology CoreP20GM103427 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Heather Colleen Jensen-Smith · 2012 to 2026
$59.2M
UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI James Eudy · 1985 to 2026
$55.0M
Tracking and Evaluation CoreU54GM115458 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ZHANG, YING · 2016 to 2025
$42.8M
NCI NIH HHS P30 CA013148NCI NIH HHS P30 CA036727NIGMS NIH HHS P20 GM103427NIGMS NIH HHS U54 GM115458
6 · The paper itself

Abstract

Purpose: Although there is an established role for microbiome dysbiosis in the pathobiology of colorectal cancer (CRC), CRC patients of various race/ethnicities demonstrate distinct clinical behaviors. Thus, we investigated microbiome dysbiosis in Egyptian, African American (AA), and European American (EA) CRC patients. Patients and methods: CRCs and their corresponding normal tissues from Egyptian (n = 17) patients of the Alexandria University Hospital, Egypt, and tissues from AA (n = 18) and EA (n = 19) patients at the University of Alabama at Birmingham were collected. DNA was isolated from frozen tissues, and the microbiome composition was analyzed by 16S rRNA sequencing. Differential microbial abundance, diversity, and metabolic pathways were identified using linear discriminant analysis (LDA) effect size analyses. Additionally, we compared these profiles with our previously published microbiome data derived from Kenyan CRC patients. Results: Differential microbiome analysis of CRCs across all racial/ethnic groups showed dysbiosis. There were high abundances of Conclusions: Our findings showed altered mucosa-associated microbiome profiles of CRCs and their metabolic pathways across racial/ethnic groups. These findings provide a basis for future studies to link racial/ethnic microbiome differences with distinct clinical behaviors in CRC.

Indexed as

African AmericanColorectal cancerEgyptianEuropean AmericanMicrobiome

Identifiers

PMID37483698
PMCPMC10362239
OpenAlexW4383552496

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.